Trial Profile

Phase III Trial Comparing Treatment With Melphalan+Prednisone (MP) With Melphalan+Prednisone+Thalidomide (MPT) for Previously Untreated Elderly Patients With Multiple Myeloma.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 17 Aug 2013

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Thalidomide (Primary) ; Melphalan; Prednisone
Indications Multiple myeloma
Focus Therapeutic Use

Most Recent Events

14 Aug 2013 Additional lead trial centre added as reported by ClinicalTrials.gov.
05 Dec 2009 Initial results from the Turkish Myeloma Study Group were presented at the 51st Annual Meeting and Exposition of the American Society of Hematology.
15 Jul 2009 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com